Director/PDMR Shareholding

DXS International

24/05/2023 12:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230524:nGNEbsDpxT&default-theme=true


DXS INTERNATIONAL PLC

Notification of Director / PDMR Dealing

The Board of DXS International plc (the “Company”), the AQSE Growth Market
quoted clinical decision support developer and supplier of clinical decision
support systems confirms that the Placing Shares and the Stakeholder Shares
referred to in the Announcement of 17th May have this morning been admitted to
trading on the Aquis Stock Exchange.

As part of the Placing and Conversion of Debt DL Services Limited, (a company
owned and controlled by the Chief Executive’s wife), has been issued with
753,244 Ordinary Shares in the Company at the Placing Price of 4p per share.

Following the transaction specified above Mr Immelman’s interests, including
those of persons closely associated with him, is 6,523,829 Ordinary Shares
representing 10.19% of the issued share capital of the Company.

 1   Details of the person discharging managerial responsibilities / person closely associated                                                                                                                                            
 a)  Name                                                         DL Services Limited                                                                                                                                                     
 2   Reason for the notification                                                                                                                                                                                                          
 a)  Position/status                                              a company owned and controlled by the Chief Executive’s wife                                                                                                            
 b)  Initial notification /Amendment                              Initial                                                                                                                                                                 
 3   Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor                                                                                                                        
 a)  Name                                                         DXS INTERNATIONAL PLC                                                                                                                                                   
 b)  LEI                                                          2138001R1KEUWTXEVJ44                                                                                                                                                    
 4   Details of the transaction(s): section to be repeated for ( i ) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted                                  
 a)  Description of the financial instrument, type of instrument  Ordinary Shares of 0.33p each                                                                                                                                           
                                                                                                                                                                                                                                          
     Identification code                                          ISIN GB00B2Q6HZ92                                                                                                                                                       
                                                                                                                                                                                                                                          
 b)  Nature of the transaction                                    Subscription                                                                                                                                                            
 c)  Price(s) and volume(s)                                                                                                                                                                                                               
                                                                                                            Price(s)                                  Volume(s)                                                                           
                                                                                                            4p                                        753,244                                                                             
                                                                                                                                                                                                                                          
 d)  Aggregated information                                                                                                                                                                                                               
                                                                                                                                                                                                                                          
     - Aggregated volume                                                                                                                                                                                                                  
                                                                                                                                                                                                                                          
     - Price                                                                                                                                                                                                                              
                                                                                                                                                                                                                                          
 e)  Date of the transaction                                      24 May 2023                                                                                                                                                             
 f)  Place of the transaction                                     Off market                                                                                                                                                              

The Directors of DXS International plc accept responsibility for this
announcement

Enquiries:

 David Immelman (Chief Executive) DXS International plc      01252 719800 david@dxs-systems.com  
 Wrecclesham House Wrecclesham Road Farnham Surrey GU10 4PS                                      
 www.dxs-systems.co.uk                                                                           



 Corporate Advisor                              
 David Papworth City & Merchant  0207 101 7676  



 Corporate Broker                                 
 Hybridan LLP Claire Louise Noyce  020 3764 2341  

Note to Editors:

DXS International presents up to date treatment guidelines and
recommendations, from Clinical Commissioning Groups and other trusted NHS
sources, to doctors, nurses and pharmacists in their workflow and during the
patient consultation. This effective clinical decision support ultimately
translates to improved healthcare outcomes delivered more cost effectively
which should significantly contribute towards the NHS achieving its projected
efficiency savings